Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Number Connection Test A, assessed using: seconds (1 trial) or Z‐score (1 trial) at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Health‐related quality of life ‐ all trials Higher scores indicate improved health‐related quality of life · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin probably leads to lower hepatic encephalopathy ‐ total number compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Blood ammonia measured in μg/mL at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Number Connection Test A, assessed using: seconds (1 trial) or Z‐score (1 trial) at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Mortality ‐ total number · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in mortality ‐ total number compared with non‐absorbable disaccharide (low certainty).
1 finding from 1 review
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (low certainty).
1 finding from 1 review
All‐cause mortality · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
ePTFE‐covered stents may leads to lower all‐cause mortality compared with bare stents (low certainty).
1 finding from 1 review
Hepatic encephalopathy · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
It is very uncertain whether ePTFE‐covered stents changes hepatic encephalopathy compared with bare stents (very low certainty).
2 findings from 1 review
Kidney failure · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
It is very uncertain whether ePTFE‐covered stents changes kidney failure compared with bare stents (very low certainty).
1 finding from 1 review
Shunt dysfunctiona · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
ePTFE‐covered stents may leads to lower shunt dysfunctiona compared with bare stents (low certainty).
1 finding from 1 review
Upper gastrointestinal bleeding · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
ePTFE‐covered stents may leads to lower upper gastrointestinal bleeding compared with bare stents (low certainty).
2 findings from 1 review
Recurrence of ascites · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
ePTFE‐covered stents may leads to lower recurrence of ascites compared with bare stents (low certainty).
2 findings from 1 review
Shunt dysfunction · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
ePTFE‐covered stents may leads to lower shunt dysfunction compared with bare stents (low certainty).
1 finding from 1 review
Total mortalitya · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
It is very uncertain whether ePTFE‐covered stents changes all‐cause mortalitya compared with bare stents (very low certainty).
1 finding from 1 review
Procedure‐related complications · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
It is very uncertain whether ePTFE‐covered stents changes procedure‐related complications compared with bare stents (very low certainty).
1 finding from 1 review
All‐cause mortality at end of intervention (range 2–10 months) · adult patients after liver transplantation.
It is very uncertain whether exercise changes all‐cause mortality at end of intervention (range 2–10 months) compared with control (very low certainty).
1 finding from 1 review
Serious adverse events (excluding deaths) at 26 weeks · adult patients after liver transplantation.
1 finding from 1 review